Centivax Secures $37 Million Investment Led By Structure Fund For Universal Flu Vaccine Development

Centivax, a South San Francisco-based developer of a universal flu vaccine, raised $37 million in a funding round led by Structure Fund. Other participants in this transaction include Meiji Seika Pharma Co., Sigmas Group, Kendall Capital Partners, and Stripe founders Patrick and John Collison.

Summary of transaction details:

• Deal Type: Funding Round
• Transaction Amount: $37,000,000
• Company Headquarters: South San Francisco, California
• Founder's Name: Dr. Jacob Glanville
• Notable Investors: Structure Fund, Meiji Seika Pharma Co., Sigmas Group, Kendall Capital Partners, Patrick Collison, John Collison

Led by CEO Jacob Glanville, Centivax aims to utilize the funding to expand operations and advance its development programs, particularly its first asset—a universal flu vaccine in GMP, which has demonstrated proof-of-concept with support from various organizations including the Bill and Melinda Gates Foundation, the Department of Defense, the Army, the Navy, and the National Institutes of Health. Additionally, Centivax's platform enables the development of broadly neutralizing therapeutics and vaccines for cancer and other indications, bolstered by a collaboration with Emery Pharma for GLP/CGMP-compliant testing initiated in 2025.